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In the greater tree of life, the “rise” of uric acid in the circu-
lation of living organisms is a relatively recent event (1). In 
the majority of species that generate uric acid as the end 
product of purine metabolism, urate is transformed into 
a more soluble allantoin by urate oxidase (“uricase”) (2). 
However, it is presently believed that some 10-20 million 
years ago 2 independent mutations in the uricase gene oc-
curred and were kept in a very small subset of species (in-
cluding the ancestors of apes and humans) – most likely 
by positive selection (3). Many elements of this story re-
main a mystery even to this date. Why did some primates 
lose uricase activity some 15 million years ago? What was 
the selective advantage of having 10-fold higher serum 
urate levels compared with other mammals? Was it related 
to the development of cognitive abilities? Did it serve as a 
protection against infectious agents of those times? Did it 
buffer the effects of oxidative stress and contribute to pres-
ent-day longevity? Why do male humans have much high-
er serum levels than female? Is uric acid a friend or a foe 
– is it a protective factor or a risk factor, and against (or for) 
what? What levels should be considered too high? Or too 
low? What causes the variation in its levels within and be-
tween humans? All these fundamental questions remain 
unanswered to this day (4,5).
Partially because of these long-standing mysteries, the 
interest in uric acid among the researchers is steadily in-
creasing. This is reflected in a growing number of articles 
related to this topic over the past decade. After studying 
several recent references that compared different search 
tools, we established that Web of Science’s search tools 
were most appropriate to our needs (6-8). We conducted 
a search of the Web of Science (9) using search terms: “uric 
acid” OR “urate” OR “hyperuric(a)emia” OR “hypouric(a)emia.” 
The search was performed for all fields for the period be-
tween 1 January, 2000 and 30 December, 2009 and it re-
turned 8715 articles. The distribution of those articles by 
year of publication is shown in Figure 1. The number of 
publications related to this topic has doubled over the pe-
riod of interest, from just above 600 in each year to more 
than 1200 in 2008. The “decrease” in 2009 is most likely an 
artifact, because there are still unprocessed articles from 
2009 that will eventually appear on the Web of Science in 
early 2010. The 8715 articles have been cited 88 508 times, 
which gives an average citation per item of 10.2 times. 
However, this indicator is not very useful because the peri-
od of citation ranged from 9 years (for articles published in 
2000) to 0 years (for articles published in 2009). Assuming 
that all the articles had a median period during which they 
could have accumulated citations anywhere between 3-4 
years (given that the majority was published in the second 
part of the decade), this gives “citation intensity” for an av-
erage article of about 3 citations in each year, which is also 
indicative of the level of activity in this field.
Table 1 shows countries, institutions, and journals of or-
igin of the articles related to uric acid, urate, hyper- or 
hypouric(a)emia published between 2000 and 2009 
and indexed by the Web of Science. Most of the ar-
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Figure 1.
The distribution of 8715 articles on the Web of Science (4) that contained 
key words “uric acid,” “urate,” “hyperuric(a)emia,” or “hypouric(a)emia” by 
the year of publication within the past decade.
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ticles came from the USA (25%), followed by Japan (10%), 
China (7%), Italy (6%), Germany (5%), England (5%), and 
Spain (5%). Two somewhat surprising entries into top 10 
are Taiwan and Turkey, which may be explained by a high 
prevalence of hyperuricemia and gout in these countries 
(10,11). Among the institutions, most of the articles were 
generated by the groups from the University of Florida, 
followed by their colleagues from Harvard University. The 
list is dominated by US institutions, with University of To-
kyo, in the 7th place, being the only non-US institution 
among the top 10. Journal of Hypertension leads the list 
of journals that were most receptive to publishing 
the research related to uric acid, with more than 14 articles 
published on this topic in each year. It is followed by Elec-
troanalysis, a couple of rheumatology journals, and two ne-
phrology journals. This list reflects our current understand-
ing of the role of uric acid in affecting blood pressure, gout, 
kidney disease, as well as its potential anti-oxidant proper-
ties. To underscore the importance of the latter, the journal 
Free Radicals Biology and Medicine is also on the list, in the 
7th place.
After this initial analysis of the number and distribution of 
the articles published during the last decade on the topic 
of uric acid, we tried to identify the 10 articles (among 8715) 
which represented the most significant breakthroughs over 
the past decade. We were particularly interested whether 
there were truly novel insights providing some answers to 
the set of fundamental questions that was outlined in the 
introduction of this article. We used the Web of Science to 
investigate the number of citations received by each of the 
8715 articles over a decade. To ensure fairness to all the ar-
ticles included in the analysis, which had different time pe-
riods following their publication to pick up citations, we did 
not rank them by the total number of citations received but 
rather by “citation intensity.” We defined “citation intensity” 
as the average number of citations received by each article 
in each year following the publication. This indicator should 
be more stable and should still recognize the achievements 
that generated the most interest among the other research-
ers, even for the articles that have been published relative-
ly recently. Only the most recently published articles (eg, 
those published in the past year) were slightly disadvan-
taged by this approach. Furthermore, we only considered 
articles that were clearly focused on uric acid, rather than 
those that were returned because of indirect interest in uric 
acid, which was not clear from the title and/or abstract. The 
10 most significant insights during the past decade accord-
ing to this indicator are shown in Table 2.
The clear “winner”, ie, the most significant research progress 
over the past decade related to uric acid, was the article by 
Martinon et al published in Nature in 2006. The authors dis-
covered a molecular mechanism by which the deposition of 
monosodium urate (MSU) or calcium pyrophosphate dihy-
drate (CPPD) crystals in hyperuricaemic patients induce in-
flammation in gout and pseudogout disease. They showed 
that MSU and CPPD engaged the caspase-1-activating 
NALP3 (also called cryopyrin) inflammasome. This results 
in the production of active interleukin (IL)-1 beta and IL-18. 
They proved their hypothesis by demonstrating that mac-
rophages from mice deficient in various components of the 
Table 1. Countries, institutions, and journals of origin of the 
articles related to uric acid, urate, hyper- or hypouricemia 
between 2000 and 2009
Rank Publication source No. %
Country
 1 United States of America 2194 25.18
 2 Japan  907 10.41
 3 PR China  626  7.18
 4 Italy  483  5.54
 5 Germany  475  5.45
 6 England  473  5.43
 7 Spain  442  5.07
 8 Taiwan  349  4.00
 9 Turkey  339  3.89
10 India  323  3.71
Institution
 1 University of Florida  134  1.54
 2 Harvard University  113  1.30
 3 University of Texas   91  1.04
 4 University Ioannina   80  0.92
 5 University of Pennsylvania   72  0.83
 6 Baylor College of Medicine   65  0.75
 7 University of Tokyo   62  0.71
 8 University of Minnesota   61  0.70
 8 University of Pittsburgh   61  0.70
10 University of Alabama   57  0.65
Journal
 1 Journal of Hypertension  143  1.64
 2 Electroanalysis  125  1.43
 3 Arthritis and Rheumatism  108  1.24
 4 Journal of Rheumatology   94  1.08
 5 Kidney International   89  1.02
 6 Nephrology Dialysis Transplantation   84  0.96
 7 Free Radical Biology and Medicine   82  0.94
 7 Journal of the American Society of Nephrology  82  0.94
 9 Biosensors & Bioelectronics   74  0.85
10 Annals of the Rheumatic Diseases   66  0.76
Rudan et al: Uric Acid: the Past Decade
www.cmj.hr
inflammasome (such as caspase-1, ASC, and NALP3) were 
defective in crystal-induced IL-1 beta activation (12). This ar-
ticle was cited about 100 times in each year after its publica-
tion, in comparison with an average of 3 in this field (9).
In the second place, there is an unexpected insight pub-
lished by Kool et al in the Journal of Experimental Medicine 
in 2008. The authors realized that the mechanism by which 
alum adjuvant boosts adaptive immunity is the induction 
of uric acid and activation of inflammatory dendritic cells. 
Alum (aluminum hydroxide) is the most widely used adju-
vant in human vaccines, but the mechanism of its adjuvan-
ticity had been unknown. The authors showed that inflam-
matory dendritic cells-driven responses were abolished in 
MyD88-deficient mice and after uricase treatment, suggest-
ing that alum adjuvant is immunogenic by exploiting “na-
ture’s adjuvant,” the inflammatory dendritic cells, through 
induction of the endogenous danger signal – uric acid (13). 
This is a potentially very significant discovery that may par-
tially explain why there was a positive selection on uricase 
mutations in some primates over the past 15 million years.
The third and fourth place are held by two epidemiological 
studies led by Johnson (14) and Fang (15) and published in 
Hypertension and JAMA, respectively. The studies used lon-
gitudinal design and large sample sizes to clarify the role of 
urate levels in hypertension and cardiovascular and renal 
disease – ie, some of the most common human diseases 
and conditions responsible for a considerable portion of 
global disease burden, both in terms of morbidity and mor-
tality. The studies suggested that increased serum uric acid 
levels were independently and significantly associated with 
risk of cardiovascular mortality and the development of hy-
pertension, vascular disease, and renal disease. Still, the au-
thors agreed that further research would be needed to es-
tablish whether the nature of these apparent associations 
was causal and what the exact molecular mechanisms 
were (14,15).
The fifth and sixth most significant articles according to 
citation intensity were both focused on understanding 
of the renal urate reabsorption system, which main-
tains high concentration of uric acid in human se-
Table 2. The 10 articles with the greatest “citation intensity” (average number of citations received per each year following the publication) among 
8715 articles indexed by the Web of Science on the topic of uric acid, urate, and hyper- and hypouric(a)emia
Rank authors Title Journal Year Volume Pages
Cumulative
citations
Citations
per year
 1 Martinon F, Petrilli V, Mayor 
A, et al.
Gout-associated uric acid crystals activate 
the NALP3 inflammasome
Nature 2006 440  237-241 402 100.50
 2 Kool M, Soullie T, van 
Nimwegen M, et al.
Alum adjuvant boosts adaptive immunity 
by inducing uric acid and activating inflam-
matory dendritic cells
Journal of Experimental 
Medicine
2008 205  869-882  85  42.50
 3 Johnson RJ, Kang DH, Feig 
D, et al.
Is there a pathogenetic role for uric acid in 
hypertension and cardiovascular and renal 
disease?
Hypertension 2003  41 1183-1190 243  34.71
 4 Fang J, Alderman MH Serum uric acid and cardiovascular mortal-
ity - The NHANES I epidemiologic follow-up 
study, 1971-1992
JAMA 2000 283 2404-2410 333  33.30
 5 Enomoto A, Kimura H, 
Chairoungdua A, et al.
Molecular identification of a renal urate-
anion exchanger that regulates blood urate 
levels
Nature 2002 417  447-452 264  33.00
 6 Vitart V, Rudan I, Hayward 
C, et al.
SLC2A9 is a newly identified urate trans-
porter influencing serum urate concentra-
tion, urate excretion and gout
Nature Genetics 2008  40  437-442  56  28.00
 7 Nakagawa T, Hu HB, 
Zharikov S, et al.
A causal role for uric acid in fructose-in-
duced metabolic syndrome
American Journal of Physi-
ology - Renal Physiology
2006 290 F625-F631 105  26.25
 8 Khosla UM, Zharikov S, 
Finch JL, et al.
Hyperuricemia induces endothelial dysfunc-
tion
Kidney International 2005  67 1739-1742 122  24.40
 9 Becker MA, Schumacher 
HR, Wortmann RL, et al.
Febuxostat compared with allopurinol in 
patients with hyperuricemia and gout
New England Journal of 
Medicine
2005 353 2450-2461 118  23.60
10 Mazzali M, Hughes J, Kim 
YG, et al.
Elevated uric acid increases blood pressure 
in the rat by a novel crystal-independent 
mechanism
Hypertension 2001  38 1101-1106 204  22.67
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rum. It was known that 70% of daily urate disposal occurs 
via the kidneys, and that in 5%-25% of the human popu-
lation hyperuricemia develops because of impaired renal 
excretion. It was also known that about 10% of people 
with hyperuricemia progress to develop gout, an inflam-
matory arthritis that results from deposition of monoso-
dium urate crystals in the joint. However, the molecular 
basis for urate handling in the human kidney was unclear 
because of difficulties in understanding diverse urate 
transport systems and species differences (16). The first 
important insight was published by Enomoto et al in Na-
ture in 2002. They identified what they thought was the 
long-hypothesized urate transporter in the human kidney 
and called it URAT1 (encoded by the gene SLC22A12). It 
was indeed a urate-anion exchanger regulating blood 
urate levels. The authors also showed that patients with 
idiopathic renal hypouricemia had defects in SLC22A12 
(16). However, in the second part of the decade one of 
the first genome-wide association studies (published 
by Vitart et al in Nature Genetics in 2008) identified ge-
netic variants within another transporter gene, SLC2A9, 
that explained much more of the variance in serum uric 
acid concentrations than URAT1. Common genetic vari-
ants in SLC2A9 were also associated with low fractional 
excretion of uric acid and with gout disease. The activity 
of SLC2A9 in uric acid transport was several times greater 
than that of the URAT1, as shown by functional experi-
ments in Xenopus laevis oocytes. This finding was entirely 
surprising because SLC2A9 was a known fructose trans-
porter. The power provided by genome-wide association 
strategies and supporting high-throughput genomic and 
bioinformatic technologies was critical in revealing its im-
portance in uric acid transport (17).
The seventh on the list is the article by Nakagawa et al 
published in American Journal of Physiology – Renal Physiol-
ogy in 2006. The authors established a causal role for uric 
acid in fructose-induced metabolic syndrome. They pro-
posed that a marked increase in total fructose intake (in 
the form of table sugar and high-fructose corn syrup) in 
the recent decades may have substantially contributed to 
the epidemic of metabolic syndrome. They proposed that 
fructose raised uric acid, which in turn inhibited nitric ox-
ide bioavailability. However, insulin requires nitric oxide to 
stimulate glucose uptake. Thus, fructose-induced hyperuri-
cemia may have a pathogenic role in metabolic syndrome. 
A series of related experiments conducted in rats provid-
ed the first evidence that uric acid may be a cause of met-
abolic syndrome, possibly due to its ability to inhibit en-
dothelial function (18).
The eighth article on the list, published by Khosla et al in 
Kidney International in 2005, was focused on the possible 
effects of hyperuricemia on the induction of endothelial 
dysfunction. The underlying hypothesis was that hyper-
uricemia generated reactive oxygen species and subse-
quent endothelial dysfunction through effects on xantine 
oxidase activity, and that inhibition of xanthine oxidase 
with allopurinol can reverse endothelial dysfunction. The 
authors further hypothesized that uric acid induced endo-
thelial dysfunction by inhibiting nitric oxide production. In 
a series of well-designed experiments in rats they showed 
that hyperuricemic rats had a decrease in serum nitric ox-
ide, which is reversed by lowering uric acid levels with al-
lopurinol, and that soluble uric acid also impaired nitric ox-
ide generation in cultured endothelial cells thus inducing 
endothelial dysfunction (19).
The ninth article in the top 10 was written by Becker et 
al and published in the New England Journal of Medicine 
in 2005. It compared the new drug Febuxostat with allo-
purinol in patients with hyperuricemia and gout. Febuxo-
stat was a novel nonpurine selective inhibitor of xanthine 
oxidase and a potential alternative to allopurinol. At a daily 
dose of 80 mg or 120 mg, Febuxostat was more effective 
than allopurinol at the commonly used fixed daily dose 
(300 mg) in lowering serum urate, while similar reductions 
in gout flares and tophus area occurred in all treatment 
groups (20).
The article which closes our list of top 10 discoveries relat-
ed to uric acid in the past decade was published by Maz-
zali et al in Hypertension in 2001. The authors tested the 
hypothesis that uric acid may have a causal role in the de-
velopment of hypertension and renal disease by examin-
ing the effects of mild hyperuricemia in rats, which was in-
duced by providing a uricase inhibitor (oxonic acid) in the 
diet. Hyperuricemic rats developed elevated blood pres-
sure after 3 weeks, whereas control rats remained normo-
tensive. The development of hypertension was prevented 
by concurrent treatment with either a xanthine oxidase in-
hibitor (allopurinol) or a uricosuric agent (benziodarone), 
both of which lowered uric acid levels. A direct relation-
ship was found between blood pressure and uric acid with 
blood pressure increase for each 0.03-mmol/L (0.5-mg/dL) 
incremental rise in serum uric acid. The rats also showed 
signs of ischemic type of injury of the kidneys with colla-
gen deposition, macrophage infiltration, and an increase 
in tubular expression of osteopontin, while both the renal 
injury and hypertension were reduced by treatment with 
enalapril or l-arginine. The authors concluded that mild hy-
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peruricemia caused hypertension and renal injury in the 
rat via a crystal-independent mechanism, with stimulation 
of the renin-angiotensin system and inhibition of neuronal 
NO-synthase (21).
In conclusion, it is clear that the past decade has brought 
a number of very important new insights about the regu-
lation of uric acid metabolism and the mechanisms that 
could potentially explain its role in conditions such as gout, 
infectious diseases, inflammation, hypertension, cardiovas-
cular disease, and renal disease. Still, many more questions 
have remained unanswered and it will take more time and 
effort to respond to some of the most fundamental ques-
tions posed in the introduction of this article. In the decade 
to come, we expect that genome-wide association studies 
will discover many genetic loci that underlie variation in 
uric acid and predict hyperuricemia, gout, and urolithiasis 
in humans and experimental animals. Further functional 
genomics follow-up should explain more general role of 
caspase-1-activating NALP3 inflammasome and strength-
en the evidence for the role of uric acid in innate immu-
nity. The link of uric acid levels with hundreds of so-called 
“metabolomics” traits will strengthen the evidence for or 
against the causal role of hyperuricaemia in cardiovascular 
and metabolic disorders.
The Croatian Medical Journal starts 2010 with a theme is-
sue on the topic of uric acid, presenting the efforts of Cro-
atian researchers who have been involved in some of the 
most significant discoveries achieved over the past sev-
eral years using the biobank resource “10,001 Dalmatians” 
(17,22-27). In this issue, Gunjača and colleagues investi-
gate for the first time the value of combining the 8 recent-
ly described genetic loci influencing serum uric acid con-
centration in prediction of hyperuricemia (28). Jerončić 
and colleagues reported on interactions between genetic 
variants in SLC2A9 and dietary habits in serum uric acid 
regulation (29). Polašek and colleagues found for the first 
time that SLC2A9 was a urate transporter associated not 
only with gout, but also with nephrolithiasis (30). Polašek 
and colleagues also found that common variants in SL-
C17A3 gene affected intra-personal variation in serum uric 
acid levels in longitudinal time series (31). Finally, Mladen 
Boban and Darko Modun reviewed the knowledge on 
the effects of red wine consumption on oxidative stress 
through temporary postprandial changes in uric acid lev-
els (32). We hope that the decade ahead will bring further 
progress and at least several unexpected insights that will 
answer some of the questions related to the role of uric 
acid in human organism.
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